Targeting PRMTs Creates Vulnerability of DNA Double-Stand Break Repair Pathways, and Potentiates Chemotherapy Efficacy in TNBC.
Saved in:
| Title: | Targeting PRMTs Creates Vulnerability of DNA Double-Stand Break Repair Pathways, and Potentiates Chemotherapy Efficacy in TNBC. |
|---|---|
| Authors: | Thiebaut C; Université Claude Bernard Lyon 1, Lyon, France.; Inserm U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France.; CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon, France., Martinez S; Université Claude Bernard Lyon 1, Lyon, France.; Inserm U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France.; CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon, France., Pruvost L; Université Claude Bernard Lyon 1, Lyon, France.; Inserm U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France.; CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon, France., Eve L; Université Claude Bernard Lyon 1, Lyon, France.; Inserm U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France.; CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon, France., El-Botty R; Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL University, Paris, France., Sourd L; Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL University, Paris, France., Montaudon E; Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL University, Paris, France., Dahmani A; Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL University, Paris, France., Derrien H; Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL University, Paris, France., Sentis S; Université Claude Bernard Lyon 1, Lyon, France.; Inserm U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France.; CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon, France., Poulard C; Université Claude Bernard Lyon 1, Lyon, France.; Inserm U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France.; CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon, France., Marangoni E; Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL University, Paris, France., Trédan O; Université Claude Bernard Lyon 1, Lyon, France.; Inserm U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France.; CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon, France.; Oncology Department, Centre Leon Bérard, Lyon, France., Le Romancer M; Université Claude Bernard Lyon 1, Lyon, France.; Inserm U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France.; CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon, France. |
| Source: | Cancer science [Cancer Sci] 2026 May; Vol. 117 (5), pp. 1273-1285. Date of Electronic Publication: 2026 Mar 09. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Wiley Publishing on behalf of the Japanese Cancer Association Country of Publication: England NLM ID: 101168776 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1349-7006 (Electronic) Linking ISSN: 13479032 NLM ISO Abbreviation: Cancer Sci Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 41801765 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Targeting PRMTs Creates Vulnerability of DNA Double-Stand Break Repair Pathways, and Potentiates Chemotherapy Efficacy in TNBC. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Thiebaut+C%22">Thiebaut C</searchLink>; Université Claude Bernard Lyon 1, Lyon, France.; Inserm U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France.; CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon, France.<br /><searchLink fieldCode="AU" term="%22Martinez+S%22">Martinez S</searchLink>; Université Claude Bernard Lyon 1, Lyon, France.; Inserm U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France.; CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon, France.<br /><searchLink fieldCode="AU" term="%22Pruvost+L%22">Pruvost L</searchLink>; Université Claude Bernard Lyon 1, Lyon, France.; Inserm U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France.; CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon, France.<br /><searchLink fieldCode="AU" term="%22Eve+L%22">Eve L</searchLink>; Université Claude Bernard Lyon 1, Lyon, France.; Inserm U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France.; CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon, France.<br /><searchLink fieldCode="AU" term="%22El-Botty+R%22">El-Botty R</searchLink>; Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL University, Paris, France.<br /><searchLink fieldCode="AU" term="%22Sourd+L%22">Sourd L</searchLink>; Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL University, Paris, France.<br /><searchLink fieldCode="AU" term="%22Montaudon+E%22">Montaudon E</searchLink>; Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL University, Paris, France.<br /><searchLink fieldCode="AU" term="%22Dahmani+A%22">Dahmani A</searchLink>; Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL University, Paris, France.<br /><searchLink fieldCode="AU" term="%22Derrien+H%22">Derrien H</searchLink>; Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL University, Paris, France.<br /><searchLink fieldCode="AU" term="%22Sentis+S%22">Sentis S</searchLink>; Université Claude Bernard Lyon 1, Lyon, France.; Inserm U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France.; CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon, France.<br /><searchLink fieldCode="AU" term="%22Poulard+C%22">Poulard C</searchLink>; Université Claude Bernard Lyon 1, Lyon, France.; Inserm U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France.; CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon, France.<br /><searchLink fieldCode="AU" term="%22Marangoni+E%22">Marangoni E</searchLink>; Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL University, Paris, France.<br /><searchLink fieldCode="AU" term="%22Trédan+O%22">Trédan O</searchLink>; Université Claude Bernard Lyon 1, Lyon, France.; Inserm U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France.; CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon, France.; Oncology Department, Centre Leon Bérard, Lyon, France.<br /><searchLink fieldCode="AU" term="%22Le+Romancer+M%22">Le Romancer M</searchLink>; Université Claude Bernard Lyon 1, Lyon, France.; Inserm U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France.; CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon, France. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101168776%22">Cancer science</searchLink> [Cancer Sci] 2026 May; Vol. 117 (5), pp. 1273-1285. <i>Date of Electronic Publication: </i>2026 Mar 09. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Wiley+Publishing+on+behalf+of+the+Japanese+Cancer+Association%22">Wiley Publishing on behalf of the Japanese Cancer Association </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101168776 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1349-7006 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2213479032%22">13479032 </searchLink><i>NLM ISO Abbreviation: </i>Cancer Sci <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41801765 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1111/cas.70338 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 1273 Titles: – TitleFull: Targeting PRMTs Creates Vulnerability of DNA Double-Stand Break Repair Pathways, and Potentiates Chemotherapy Efficacy in TNBC. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Thiebaut C – PersonEntity: Name: NameFull: Martinez S – PersonEntity: Name: NameFull: Pruvost L – PersonEntity: Name: NameFull: Eve L – PersonEntity: Name: NameFull: El-Botty R – PersonEntity: Name: NameFull: Sourd L – PersonEntity: Name: NameFull: Montaudon E – PersonEntity: Name: NameFull: Dahmani A – PersonEntity: Name: NameFull: Derrien H – PersonEntity: Name: NameFull: Sentis S – PersonEntity: Name: NameFull: Poulard C – PersonEntity: Name: NameFull: Marangoni E – PersonEntity: Name: NameFull: Trédan O – PersonEntity: Name: NameFull: Le Romancer M IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 05 Text: 2026 May Type: published Y: 2026 Identifiers: – Type: issn-electronic Value: 1349-7006 Numbering: – Type: volume Value: 117 – Type: issue Value: 5 Titles: – TitleFull: Cancer science Type: main |
| ResultId | 1 |